Active, Not RecruitingPhase 1DMT

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

Sponsored by Yale University

NCT ID
NCT04711915
Target Enrollment
30 participants
Start Date
2021-03-17
Est. Completion
2026-12-01

About This Study

The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Conditions Studied

Major Depressive DisorderDepression

Interventions

  • •0.1 mg/kg Dimethyltryptamine (DMT)
  • •0.3 mg/kg Dimethyltryptamine (DMT)

Eligibility

Age:21 Years - 65 Years
Healthy Volunteers:Yes
View full eligibility criteria
Healthy controls inclusion criteria:

* Medically healthy
* Psychiatrically healthy

Healthy controls exclusion criteria:

* Unstable medical conditions
* Psychiatric illness

Depression inclusion criteria:

* Medically healthy
* Diagnosis of major depressive disorder

Depression exclusion criteria:

-Unstable medical conditions

Study Locations (1)

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut, United States

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans | Huxley